1 Open label phase I/II clinical trial and predicted efficacy of SARS-CoV-2 RBD protein vaccines

2 SOBERANA 02 and SOBERANA Plus in children

- 3 Authors: Rinaldo Puga-Gómez^{1,2}, Yariset Ricardo-Delgado¹, Chaumey Rojas-Iriarte³, Leyanis
- 4 Céspedes-Henriquez⁴, Misleidys Piedra-Bello¹, Dania Vega-Mendoza¹, Noelvia Pestana Pérez¹, Beatriz
- 5 Paredes-Moreno⁵, Meiby Rodríguez-González⁵, Carmen Valenzuela-Silva⁶, Belinda Sánchez-Ramírez⁷,
- 6 Laura Rodríguez-Noda⁵, Rocmira Pérez-Nicado⁵, Raul González-Mugica⁵, Tays Hernández-García⁷,
- 7 Talía Fundora-Barrios⁷, Martha Dubet Echevarría⁸, Juliet María Enriquez-Puertas⁸, Yenicet Infante
- 8 Hernández⁸, Ariel Palenzuela-Díaz⁹, Evelyn Gato-Orozco⁹; Yanet Chappi-Estévez¹⁰, Julio Cesar
- 9 Francisco-Pérez¹¹, Miladi Suarez Martinez⁴, Ismavy C. Castillo-Quintana⁵, Sonsire Fernandez-Castillo⁵,
- 10 Yanet Climent-Ruiz⁵, Darielys Santana-Mederos⁵, Yanelda García-Vega7, María Eugenia Toledo-
- 11 Romani¹², Delaram Doroud¹³, Alireza Biglari¹³, Yury Valdés-Balbín⁵, Dagmar García-Rivera^{5*}, Vicente
- 12 Vérez-Bencomo^{5*} and SOBERANA Research Group.

13 1. Pediatric Hospital "Juan Manuel Marquez", Av. 31, Marianao, Havana 11400, Cuba

- 14 2. Central Clinic "Cira García". St. 20, # 4101, Miramar, Playa, La Habana 11300, Cuba
- 15 3. Policlinic "5 de Septiembre"; Av. 7th, Santa Fé, Playa, La Habana, 11600, Cuba
- 16 4. Policlinic "Carlos J. Finlay"; Av, 51 and 124, Marianao, La Habana 11400, Cuba
- 5. Finlay Vaccine Institute. Av. 21 · #19810, Atabey, Playa, Havana 11600, Cuba
- Cybernetics, Mathematics and Physics Institute. 15th Street #55, Vedado, Plaza de la
 Revolución, La Habana 10400, Cuba.
- Centre of Molecular Immunology. Av 15th. and 216 Street, Siboney, Playa, Havana 11600,
 Cuba.
- 8. National Civil Defense Research Laboratory. San José de Las Lajas, Mayabeque 32700, Cuba
- 9. Centre for Immunoassays. 134 St and 25, Cubanacán, Playa, La Habana, 11600 Cuba
- 10. National Clinical Trials Coordinating Center. Av. 5th and 62 Street, Miramar, Playa, Havana
 11300, Cuba.
- 26 11. Pediatric Hospital "Borrás-Marfán". St. 17 #. 801, Vedado, La Habana, 10400. Cuba
- 12. "Pedro Kourí" Tropical Medicine Institute. Av "Novia del Mediodía", Kv 6 1/2, La Lisa, Habana,
 11400, Cuba
- 13. Pasteur Institute of Iran. No. 69, Pasteur Ave., Tehran 1316943551, Islamic Republic of Iran
- 30
- 31 Soberana Research Group:
- 32 María Elena Mesa-Herrera¹, Yarmila García-Cristiá¹, Leonor Verdecia-Sánchez¹, Misleidys Piedra-
- Bello¹, Dania Vega-Mendoza¹, Rafael del Valle Rodríguez¹, Yudalvies Oquendo-de la Cruz¹, Noelvia
- Pestana-Pérez¹, Daysi Álvarez-Montalvo¹, Randy Grillo-Fortún¹, Liset López-González¹, Omaida Fonte
- .NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 35 Galindo⁴, Yeseni Reyes-González⁴, Ana Beatriz González-Alvarez⁴, Linet Gorrita-Mora⁴, Rodrigo

36 Valera-Fernández⁵, Ivis Ontivero-Pino⁵, Marisel Martínez-Pérez⁵, Esperanza Caballero-Gonzalez⁵,

- 37 Aniurka Garcés-Hechavarría⁵, Dayle Martínez-Bedoya⁵, Maite Medina-Nápoles⁵, Yeney Regla
- 38 Domínguez-Pentón⁵, Yadira Cazañas-Quintana⁷, Thais Fundora Barrios⁷, Diana R. Hernández
- **39** Fernández⁷, Gretchen Bergado-Báez⁷, Ivette Orosa-Vazquez⁷, Franciscary Pi-Estopiñan⁷, Marianniz
- 40 Díaz-Hernández⁷, Otto Cruz-Sui⁸, Enrique Noa-Romero⁸, Arilia García-López¹⁰, Sandra Rivadereira
- 41 Muro¹⁰ Gerardo Baro-Roman⁹
- 42

43 Abstract:

- 44 *Objectives:* To evaluate heterologous vaccination scheme in children 3-18 y/o combining two SARS-
- 45 CoV-2 r-RBD protein vaccines.
- 46 *Methods*: A phase I/II open-label, adaptive and multicenter trial evaluated the safety and
- 47 immunogenicity of two doses of SOBERANA02 and a heterologous third dose of SOBERANA Plus in
- 48 350 children 3-18 y/o in Havana Cuba. Primary outcomes were safety (in phase I) and
- 49 safety/immunogenicity (in phase II) measured by anti-RBD IgG ELISA, molecular and live-virus
- 50 neutralization titers and specific T-cells response. A comparison with adult 's immunogenicity and
- 51 prediction of efficacy were done based on immunological results
- *Results*: Local pain was the unique adverse event with frequency >10%, none was serious or severe.
- 53 Two doses of SOBERANA 02 elicited humoral immune response similar to natural infection; the third
- 54 dose increased significantly the response in all children, similar to that achieved in vaccinated young
- adults and higher than in convalescents children. The neutralizing titer was evaluated in a participant's
- subset: GMT was 173.8 (CI 95% 131.7; 229.5) vs. alpha, 142 (CI 95% 101.3; 198.9) vs. delta and 24.8
- 57 (CI 95% 16.8; 36.6) vs. beta. An efficacy > 90% was estimated.
- 58 *Conclusion*: The heterologous scheme was safe and immunogenic in children 3-18 y/o.
- 59 Trial registry: https://rpcec.sld.cu/trials/RPCEC00000374
- 60
- Keywords: COVID-19; SARS-CoV-2; conjugate vaccine; pediatric vaccine, heterologous scheme;
 subunit vaccine
- 63
- 64

65 Introduction

- 66 Children protection against COVID-19 is pivotal for controlling virus dissemination and reducing disease
- 67 incidence. COVID-19 cases and hospitalizations among children and adolescents, firstly driven by the
- 68 delta variant and recently by omicron, have risen sharply even in countries with high adult vaccination
- 69 coverage (Delahoy et al., 2021; Elliott et al., 2021). This context has accelerated the clinical trials of
- 70 anti-SARS-CoV-2 vaccines for children (Xia et al., 2021; Han et al., 2021; Ali et al., 202; Frenck et al.,
- 71 2021; Walter et al., 2021; Wallace et al., 2021).
- For more than 30 years the Finlay Vaccine Institute has produced tetanus toxoid-conjugated vaccines,
- applied to children worldwide; their safety has been extensively proved through hundreds of millions of
- doses (Verez-Bencomo et al., 2004; Huang and Wu., 2010). SOBERANA 02 immunogen is anti SARS-
- 75 CoV-2 recombinant RBD conjugated to tetanus toxoid (Valdes-Balbin et al., 2021a; 2021b). It is the
- vinique conjugate vaccine in WHO's vaccine pipeline (WHO COVID-19, 2021). T-cell epitopes present
- in tetanus toxoid were expected to promote RBD specific B- and T-cell memory, and high affinity,
- 78 longstanding RBD IgG antibodies.
- **79** SOBERANA 02 has proved its safety and immunogenicity in adults 19-80 y/o; after two doses, its
- 80 efficacy was 71%. Combined with a third dose of SOBERANA Plus (recombinant RBD dimer vaccine) in
- a three-dose heterologous scheme, efficacy increased to 92.4% (Toledo-Romani et al., 2021a; 2021b;
- 82 2021c). On August 2021, the Cuban Regulatory Authority granted their emergency use authorization in
- adults, being since then extensively applied nationally for preventing COVID-19 in Cuba (CECMED,
- 84 2021).
- Here, we report the results of an open label phase I/II clinical trial in children 3-18 y/o to evaluate the
- safety and immunogenicity of two doses of SOBERANA 02 and a third dose of SOBERANA Plus. We
- avoided a placebo-controlled trial in this age group due to ethical concerns (Dal-Ré and Caplan., 2021);
- 88 alternatively, a recommended comparison (or immunobridging) with adult's immunogenicity was
- established (FDA, 2021) and the clinical efficacy was estimated based on immunological results.

90 Method

91 Study design

- 92 We designed a phase I/II study, open-label, adaptive and multicenter to evaluate the safety,
- reactogenicity and immunogenicity of two doses of SOBERANA02 and a heterologous third dose of
- 94 SOBERANA Plus in children (3-11 y/o) and teenager (12-18 y/o). Two interim analyses would decide
- 95 interruption/continuation of the study, depending on serious adverse events (AEs) during phase I.

96 Phase I was conceived in two-step, incorporating firstly 25 children 12-18 y/o (sequence 1). The first

- 97 interim report (no serious AE detected) seven days after their vaccination allowed incorporating 25
- children aged 3-11 (phase 1, sequence 2 and starting phase II in 12-18 y/o (n=150). A second interim
- report seven days after sequence 2 (no serious AE detected) allowed starting phase II in children 3-11

100 y/o (n=150). (Figure 1). Detailed information on trial sites is presented in Supplementary Material I

- 101 Children were recruited at community level across the primary health system by medical doctors. They
- were included following physical examination, parent interview and, for phase I, clinical laboratory
- assays. Key inclusion criteria were weight-height nutritional assessment; physical examination without
- alterations; clinical laboratory results within the range of reference values (only phase I) and
- microbiology laboratory tests. Key exclusion criteria were any acute infection, previous or current history
- of SARS CoV-2 infection and being a contact of a positive COVID-19 case. A detailed description of
- selection criteria appears in Supplementary Material II.
- 108 Ethical issues

109 The trial was approved by the Ethical Committee at the "Juan Manuel Marquez" Pediatric Hospital and

endorsed by the Cuban National Pediatric Group. The Cuban National Regulatory Agency (Centre for

- 111 State Control of Medicines and Medical Devices, CECMED) approved the trial (June10th, 2021,
- 112 Authorization Reference: 05.010.21BA).
- 113 Independent Data Monitoring Committees formed by five external members specialized on pediatric
- clinical practice; immunology and statistics were in charge of two interim analyses during phase I.
- 115 The trial was conducted according to Helsinki's Declaration, Good Clinical Practice and the Cuban
- 116 National Immunization Program. During recruitment, the medical investigators provided to the parents,
- both orally and written, all information about the vaccine and potential risks and benefits. Written
- informed consent was obtained from both parents; children ≥over 12 y/o should assent. The decision to
- 119 participate was not remunerated.
- 120 The National Clinical Trials Coordinating Centre (CENCEC) was responsible for monitoring the trial in121 terms of adherence to the protocol, to Good Clinical Practice and data accuracy.
- 122 Trial registry: RPCEC00000374 (Cuban Public Registry of Clinical Trials and WHO International Clinical
- 123 Registry Trials Platform) (IRCT, 2021).
- 124 Products under evaluation
- SOBERANA 02 (RBD chemically conjugated to the carrier protein tetanus toxoid) and SOBERANA Plus
- 126 (RBD dimer), adjuvated in alumina hydroxide were produced at the Finlay Vaccine Institute and the
- 127 Centre for Molecular Immunology, in Havana, Cuba, under GMP conditions. Both are subunit vaccines

based SARS-CoV-2 RBD, sequence Arg319-Phe541 produced in genetically modified CHO cells.

- 129 Formulations are detailed in Supplementary Material III-Table S1.
- 130 Product batches used: SOBERANA 02 (E1002S02X, E1002S02); SOBERANA Plus (E1001SP).
- 131 Procedures
- 132 RT-PCR SARS-CoV-2 was performed to all participants at least 72 hours before each dose. Participants
- 133 with negative PCR results received the vaccine by intramuscular injections in the deltoid region.
- 134 Immunization schedule: two doses of SOBERANA 02 and a heterologous third dose of SOBERANA
- 135 Plus 28 days apart (immunization on days 0, 28, 56). After each immunization, participants were on-site
- evaluated during one hour. Medical controls visits were planned at 24, 48 and 72 hours, and on days 7,
- 137 14 and 28 after each dose. AEs were parents-registered daily. Serum samples were collected on day 0
- (before vaccination) and 14 days after the second and the third dose (days 42 and 70). Peripheral
- blood mononuclear cells were obtained before vaccination and after the third dose (day 70) in a
- 140 participants' subset of 45 children randomly selected in each age subgroup.
- 141 Outcomes
- 142 Primary outcomes. Phase I: occurrence of serious AEs, measured daily during 28 days after each dose.
- Phase II: % of subjects with seroconversion ≥4 fold increase of IgG anti-RBD over pre-immunization, on
 days 42 and 70.
- Secondary outcomes. Phase I and phase II: Solicited local and systemic AEs, measured during 7 days
 after each dose; unsolicited AEs, measured during 28 days after each dose; neutralizing antibody titers
 (on days 42 and 70, on a sample subset), inhibition of RBD-hACE2 interaction (on days 42, 70). Phase
 II: Occurrence of serious AEs, measured during 28 days after each dose. Outcomes are detailed in
 Supplementary Material III).
- 150 Outcomes and safety assessment are detailed in Supplementary Material IV and V.
- 151 Immunogenicity assessment
- 152 Immunogenicity was evaluated by: a) quantitative ultramicro ELISA (UMELISA SARS-CoV-2 anti- RBD;
- b) competitive ELISA determined the inhibitory capacity of antibodies for blocking the RBD-hACE2
- interaction, expressed as % inhibition and molecular virus neutralization titer (mVNT₅₀); c) conventional
- virus neutralization titer (cVNT₅₀) vs. D614G, alpha, beta, and delta variants; d) RBD-specific T-cell
- response producing IFN- γ and IL-4. Immunogenicity assessment and techniques are described in
- 157 Supplementary Material VI. All immunological evaluations were performed by external laboratories from
- the Centre for Immunoassays, Centre of Molecular Immunology and National Civil Defense Research

159 Laboratory. T cell response was evaluated at Finlay Vaccine Institute. A detailed description of

immunogenicity assessment and techniques are described in Supplementary Material VI.

161 Children Convalescent Serum Panel

A Cuban children convalescent serum panel (CCCSP) was made with sera from 82 patients (3-18 y/o)

recovered from COVID-19. Detailed information about panel composition and immunocharacterization is

164 presented in Supplementary Material VII

165 Statistical analysis

166 For phase I, the calculation of sample size was done considering a two-sided 95% confidence interval for

one proportion with a width equal to 0.09 to estimate a serious AE rate <1%. For phase II a similar method

was used to estimate a seroconversion around 50%, with a lower bound of the confidence interval >30%

169 (trial hypothesis) and a dropout of 20%. This resulted in a sample size of 350 subjects (including subjects

- 170 from phase I). Detailed statistical tools, procedures and definitions are presented in Supplementary
- 171 Material VIII.

172 Results

Figure 1 and Table 1 describe the study design and demographic characteristics of the participants.

174 From 11th June to 14th July 2021, 426 children (3-18 y/o) were recruited, 350 that accomplished

selection criteria were included, and 306 completed the study. There was a balanced ratio on sex and


ethnicity; mean age was 11.3 years (SD 4.5).

Phase I started by vaccinating 25 children 12-18 y/o with SOBERANA 02; the first interim analysis done
seven days after vaccination indicated absence of serious AEs. In consequence, the trial proceeded to
phase I, sequence 2, incorporating 25 children aged 3-11 and 150 children aged 12-18 of phase II. The
second interim analysis showed no serious AE in children 3-11 y/o (sequence 2); the trial completed
phase II vaccinating 150 children 3-11 y/o with SOBERANA 02 first dose.

- 182
- 183
- 184
- 185
- 186
- 187
- 188

medRxiv preprint doi: https://doi.org/10.1101/2022.03.03.22271313; this version posted March 18, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



		Age groups	
	3-11 years	12-18 years	Total
Ν	175	175	350
Sex			
Female	80 (45.7%)	83 (47.4%)	163 (46.6%)
Male	95 (54.3%)	92 (52.6%)	187 (53.4%)
Skin colour			
White	122 (69.7%)	116 (66.3%)	238 (68.0%)
Black	9 (5.1%)	11 (6.3%)	20 (5.7%)
Multiracial	44 (25.1%)	48 (27.4%)	92 (26.3%)
Age (years)			
Mean (SD)	7.4 (2.5)	15.1 (2.1)	11.3 ± 4.5
Median (IQR)	8.0 (5.0)	15.0 (4.0)	11.5 ± 7.0
Range	3; 11	12;18	3-18
Weight (kg)			
Mean (SD)	29.4 (10.1)	54.7 (9.0)	42.0 ± 15.9
Median (IQR)	27.5 (14.0)	55.0 (13.0)	43.0 ± 27.7
Range	13.0; 58.0	32.0; 80.0	13.0; 80.0
Height (cm)			
Mean (SD)	129.1 (17.2)	164.3 (9.6)	146.7 ± 22.5
Median (IQR)	131.0 (26.0)	164.0 (13.0)	151.0 ± 34.0
Range	92; 172	142; 190	92-190
BMI (kg/m ²)			
Mean (SD)	17.0 (2.0)	20.2 (2.3)	18.6 ± 2.7
Median (IQR)	16.7 (2.7)	19.9 (3.8)	18.3 ± 4.1
Range	13.2; 22.8	14.6; 25.5	13.2-25.5

Table 1: Demographic characteristics of subjects included in the clinical trial 217

Data are n (%) unless otherwise specified. Mean (SD)=Mean ± Standard Deviation. Median (IQR)=Median ± Interguartile Range. BMI=Body mass index. Range=(Minimum; Maximum)

- During the vaccination scheme, 86 children (53.1%) suffered at least one AE; frequency was higher 219 (60%) in teenagers than in young children (46.3%). Severe and serious vaccine-associated AEs (VAAE) 220 did not occur (Table 2). Local AE predominated; the most common was local pain (47.7%), all others 221 222 had frequencies <5%; only 1.1% reported fever. More than 90% of AEs were classified as mild and lasted ≤72 hours, and 88.5% were associated with vaccination (Table 3, Supplemental Material IX-223 Table S2). AEs were more frequent after the first dose than after the second and the third dose 224 (Supplemental Material IX-Table S3). Few unsolicited adverse events were recorded (Supplemental 225 Material V-Table S4). No clinically relevant changes were observed in hematology and blood chemistry 226 analyses (Supplemental Material IX-Table S5). 227 228
- 229
- 230

Table 2: General characteristics of adverse events 231

	Age groups	
3-11 years	12-18 years	Total
175	175	350
81 (46.3%)	105 (60.0%)	186 (53.10%)
76 (43.4%)	101 (57.7%)	177 (50.6%)
0 (0.0%)	1 (0.6%)	1 (0.3%)
0 (0.0%)	0 (0.0%)	0 (0.0%)
0 (0.0%)	0 (0.0%)	0 (0.0%)
0 (0.0%)	0 (0.0%)	0 (0.0%)
141	182	323
135 (95.7%)	167 (91.8%)	302 (93.5%)
6 (4.3%)	15 (8.2%)	21 (6.5%)
0 (0.0%)	0 (0.0%)	0 (0.0%)
0 (0.0%)	1 (0.5%)*	1 (0.3%) *
118 (83.7%)	147 (80.8%)	265 (82.0%)
23 (16.3%)	35 (19.2%)	58 (18.0%)
126 (89.4%)	160 (87.9)	286 (88.5%)
0 (0.0%)	0 (0.0%)	0 (0.0%)
0 (0.0%)	0 (0.0%)	0 (0.0%)
	175 81 (46.3%) 76 (43.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 141 135 (95.7%) 6 (4.3%) 0 (0.0%) 118 (83.7%) 23 (16.3%) 126 (89.4%) 0 (0.0%) 0 (0.0%)	175 175 $81 (46.3\%)$ $105 (60.0\%)$ $76 (43.4\%)$ $101 (57.7\%)$ $0 (0.0\%)$ $1 (0.6\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ 141 182 $135 (95.7\%)$ $167 (91.8\%)$ $6 (4.3\%)$ $15 (8.2\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $0 (0.0\%)$ $1 (0.5\%)^*$ $118 (83.7\%)$ $147 (80.8\%)$ $23 (16.3\%)$ $35 (19.2\%)$ $126 (89.4\%)$ $160 (87.9)$ $0 (0.0\%)$ $0 (0.0\%)$

Data are n (%). AE=Adverse Event. VAAE=Vaccine-Associated Adverse Event; * Serious AE: Dengue required hospitalization.

Table 3: Frequency of solicited adverse events 232

		Age groups	
	3-11 years	12-18 years	Total
Ν	175	175	350
Subjects with some AE	81 (46.3%)	105 (60.0%)	186 (53.10%)
Subjects with solicited local AE			
Any	74 (42.3%)	98 (56.0%)	172 (49.1%)
Local pain	69 (39.4%)	98 (56.0%)	167 (47.7%)
Swelling	9 (5.1%)	2 (1.1%)	11 (3.1%)
Local warm	4 (2.3%)	0 (0.0%)	4 (1.1%)
Erythema	5 (2.9%)	1 (0.6%)	6 (1.7%)
Induration	5 (2.9%)	1 (0.6%)	6 (1.7%)
Subjects with solicited systemic AE			
Any	5 (2.9)	4 (2.3)	9 (2.6)
General discomfort	1 (0.6%)	3 (1.7%)	4 (1.1%)
Fever (≥38 °C)	2 (1.1)	1 (0.6)	3 (0.9)
Low-grade fever (<38 °C)	4 (2.3)	1 (0.6)	5 (1.4)
Data are n (%) unless otherwise specifie	d. AE=Adverse Eve	ent	•

- 233 Before vaccination, 97.1 % of children were negative for anti-RBD antibodies, median anti-RBD IgG was
- 1.95 UA/mL (25th-75th percentile 1.95; 1.95). Two doses of SOBERANA 02 induced seroconversion in
- 96.2% participants (CI 95% 93.5; 98.0), satisfying the trial hypothesis (>50% of seroconversion with a
- lower boundary of the two-sided 95% confidence interval >0.3) (Table 4). By age subgroup,
- 237 seroconversion was 99.4% (CI 95% 96.5; 99.9) in children 3-11 y/o and 93.1% (CI 95% 88.0; 96.5) in
- 238 12-18 y/o. Global seroconversion index was 27.8 (42.6 in children 3-11 y/o, 24.8 in 12-18 y/o); the
- median anti-RBD IgG was 57.0 UA/mL (25th-75th percentile 29.8; 153.4), being higher in younger
- children (93.3 UA/mL; 25th-75th percentile 39.0; 214.4). Specific antibody response was higher than the
- elicited by natural infection, evaluated in Cuban children convalescent panel (anti-RBD IgG median
- 11.5; 25th-75th percentile 5.3; 24.2). The heterologous third dose increased seroconversion to 100% and
- seroconversion index to 154.5; anti-RBD IgG titers also increased significantly (p<0.005) to 325.7
- 244 UA/mL (25th-75th percentile 141.5; 613.8) (Table 4).
- The capacity of anti-RBD IgG for blocking RBD- hACE2 interaction after two doses of SOBERANA 02
- was 67.4 % (25th-75th percentile 42.1; 86.9) and the mVNT₅₀ was 198.5 (CI 95% 168.4; 233.9); both
- increased significantly (p<0.005) after the third dose to 92.4 % (25th-75th percentile 88.3; 93.5) and 1261
- (CI 95% 1105,5; 1438.8) respectively. These values were higher among the youngers (3-11 y/o) after
- the second dose, but were similar in both age subgroups after the third dose. After both two and three
- doses mVNT50 was higher than after natural infection (Table 4).
- After two doses of SOBERANA 02 the neutralizing titer versus D614G variant was higher (GMT 26.4 Cl 95% 20.2; 34.5) than the children convalescent panel value (GMT 9.2 Cl 95% 6.8; 12.5); and the third dose significantly (p<0.005) boosted the response to GMT 158.4 (Cl 95% 123.0; 204.0). The neutralizing titer versus the variants alpha, beta and delta was evaluated in 48 children; 100% had neutralizing antibodies vs. alpha and delta; 97.9% vs. beta (Table 5). GMT was 173.8 (Cl 95% 131.7; 229.5) vs. alpha, 142 (Cl 95% 101.3; 198.9) vs. delta and 24.8 (Cl 95% 16.8; 36.6) vs. beta (a 2.2-fold decrease for delta and 7.0-fold decrease for beta compared to D614G).
- There was a good correlation among all humoral immunological variables, with coefficients >0.7 (Supplemental Material X-Table S6). Predictive cut-off for attaining cVNT₅₀ over 50 was estimated by ROC curve as: 192.2 AU/ml for IgG concentration, 87.1% for the inhibition of RBD:hACE2 and 427 for mVNT₅₀ (Supplemental Material X-Table S7, Figure S1)

		Age groups			CCCSP			
		3-11 years		12-18 years		Total		
		Post-2 nd dose	Post-3 rd dose	Post-2 nd dose	Post-3 rd dose	Post-2 nd dose	Post-3 rd dose	-
	Ν	159	156	159	150	318	306	82
Anti-RBD IgG	N (%)	157/158 (99.4)	155/155 (100.0)	148/159 (93.1)	150/150 (100%)*	305/317 (96.2)	305/305 (100.0)*	N.D
seroconversion rate	95% CI	96.5; 99.9	99.6; 100.0	88.0; 96.5	99.6; 100.0	93.5; 98.0	99.8; 100.0	
Anti-RBD IgG	Median	93.3	329.8*	49.9	325.6*	57.0	325.7*	11.5
AU/mL	25 th -75 th	39.0; 214.4	162.9; 685.6	22.3; 90.7	108.0; 555.8	29.8; 153.4	141.5; 613.8	5.3; 24.2
Seroconversion	Median	42.6	155.4*	24.8	154.3*	27.8	154.5*	N.D
index	25 th -75 th	19.5; 97.0	75.4; 260.2	11.0; 44.7	50.2; 266.3	14.3; 69.0	67.2; 260.9	
RBD:hACE2	Median	78.3	92.5*	60.1	92.2*	67.4	92.4*	20.8
Inh%	25 th -75 th	49.4; 88.9	88.8; 93.4	36.7; 79.7	87.7; 93.6	42.1; 86.9	88.3; 93.5	10.9; 40.8
mVNT ₅₀	GMT	274.1	1418.3*	143.7	1116.2*	198.5	1261.2*	35.2
	95% CI	216.8; 346.5	1180.0; 1704.7	115.0; 179.5	924.0; 1348.3	168.4; 233.9	1105.5; 1438.8	25.3; 48.9
cVNT ₅₀	Ν	63	66	60	65	123	131	70
vs D614G	GMT	28.4	181.6*	24.4	137.9*	26.4	158.4*	9.2
	95% CI	18.5; 43.6	120.6; 273.3	17.6; 40.0	101.8; 186.9	20.2; 34.5	123.0; 204.0	6.8; 12.5

Table 4: Humoral immune response induced after two doses of SOBERANA 02 and a third heterologous doses with SOBERANA Plus.

To or baseline anti-RBD IgG 1.95 (25th-75th percentile: 1.95; 1.95) for both age subgroups and total. ND: Not determined

Anti-RBD IgG seroconversion rate: % of subjects with seroconversion (CI 95%).

Seroconversion index: increase of IgG concentration respect to baseline (median; 25th-75th percentile)

AU/mL=anti-RBD IgG concentration expressed in arbitrary units/mL.

RBD:hACE2 Inh%: RBD:hACE2 inhibition % at a serum dilution 1/100.

mVNT₅₀: molecular virus neutralization titer; as serum dilution inhibiting 50% of RBD:hACE2 interaction.

cVNT₅₀: conventional live-virus neutralization titer.

GMT=Geometric Mean Titer. 95% CI= 95% Confidence Interval; 25th-75th=25-75 percentile.

* p<0.005 versus Post - 2nd dose McNemar test (anti-RBD IgG seroconversion %), Wilcoxon Signed Ranks test (anti-RBD IgG AU/mL, RBD:hACE2 Inh%) or Paired Student t test (mVNT₅₀, cVNT₅₀, log-transformed). CCCSP=Cuban children convalescent serum panel

Table 5. Conventional live-virus neutralization titers against SARS-CoV-2 variants alpha, delta and beta.

		D614G	Alpha	Delta	Beta
cVNT ₅₀	N	48	48	48	48
	GMT	173.8	142.0	76.8*	24.8*
	95% CI	131.7; 229.5	101.3; 198.9	54.8; 107.7	16.8; 36.6

Sera from 48 children vaccinated with complete schedule (two doses SOBERANA 02 + one dose SOBERANA Plus, 28 days apart) were evaluated against D614G, alpha, delta and beta variants. cVNT₅₀=conventional live-virus neutralization titer. GMT=Geometric Mean Titer. 95% CI= 95% Confidence Interval. * p<0.005 Paired Student t test (cVNT₅₀, log-transformed) respect to D614G variant.

266


267 RBD-specific T cell response in a subset of 45 participants fully vaccinated was determined by

268 measuring IFN-y and IL-4 expression in peripheral blood mononuclear cells. The number of IFN-y and

269 IL-4 secreting cells was statistically higher (p<0.001) than their baseline levels (Figure 2), suggesting a

270 mixed Th1/Th2 profile. IFN-y expression was higher in older children while IL-4 was higher in younger

children, evidencing differences in the balance Th1/Th2.



272

Figure 2. IFN-γ- and IL-4-secreting cells in peripheral blood mononuclear cells stimulated with RBD.
Children 3-11 (N=24) and 12-18 years old (N=21) received two doses (on days 0, 28) of SOBERANA 02
and a heterologous third dose (on day 56) of SOBERANA Plus. p value represents the statistic
differences as indicated.

277

The safety and immune response in children were compared with all young adults (aged 19-39)

vaccinated in phase I and phase II studies with the same vaccines, as recommended by FDA, 2021;

safety profile was similar in both (Supplemental Material X-Table S8, S9, Figure S2). An

immunobridging analysis was performed for anti-RBD IgG, mVNT₅₀ and cVNT₅₀ between children and

young adults. IgG elicited after two doses of SOBERANA 02 was 57.0 UA/ml (25th-75th percentile 29.8;

153.4), while for young adults it was 46.4 (25th-75th percentile 17.4; 108.8); after the heterologous third

dose of SOBERANA Plus these values increased to 325.7 (25th-75th percentile 141.5; 613.8) in children 284 and 228.0 (25th-75th percentile 95.8; 394.3) in young adults. mVNT₅₀ was 198.5 (IC 95% 168.4; 233.9) in 285 children after the second dose and 1261.2 (IC 95% 1105.5; 1438.8) after the third; in young adults were 286 94.9 (IC 95% 75.0; 120.2) and 503.7 (IC 95% 432.6; 586.6) after two and three doses (Figure 3). We 287 found significant differences (p<0.05) for IgG and mVNT₅₀ between 3-18 y/o children and 19-39 y/o 288 young adults; higher values were obtained in children after both the second and the third dose. Viral 289 neutralization titers after the second dose were measured at different time points in children and young 290 adults (on day 42 in children and day 56 in young adults), making their comparison only approximate. 291

292




Figure 3: Immunobridging comparison of humoral immune response elicited in children (3-18 y/o)
respect to young adults (19-39 y/o from Phase I and II clinical trial), after two doses of SOBERANA 02
(day 42) and a third dose of SOBERANA Plus (day 70). A) anti-RBD IgG median (25th-75th percentile);
B) mVNT₅₀ GMT (CI 95%); C) cVNT₅₀ GMT (CI 95%). Bleeding was on day 42 and 70 (14 days after
second or third dose), except for cVNT50 adults after second dose was on day 56. Mann-Whitney U test
(anti-RBD IgG AU/mL) or Student t test (mVNT₅₀, cVNT₅₀, log-transformed).

- 300
- 301
- 302
- 303

304 The non-inferiority analysis was performed with cVNT₅₀ data, following FDA recommendation (FDA,

2021). After three doses (on day 70), cVNT₅₀ in children was 158.4 (IC 95% 123.0; 204.0) and 122.8

306 (80.2; 188.0) for young adults (n=43, data available) (Figure 3). The immune response in 3-18 y/o, as

- well as in age subgroups 3-11 y/o and 12-18 y/o was non-inferior to that observed in 19-39 y/o young
- adults. The geometric mean ratio (3-18 y/o value to young adult's value) for cVNT₅₀ 14 days after the
- third dose was 1.25 (CI 95% 0.77; 2.02) (Table 6), which met the non-inferiority criterion (i.e., a lower
- boundary of the two-sided 95% confidence interval of >0.67). In summary, both age groups (3-11 y/o
- and 12-18 y/o) met the non-inferiority criterion.
- 312

Table 6: Immunobridging of cVNT₅₀ in children and young adults after heterologous scheme (two doses of SOBERANA 02 and a third heterologous doses of SOBERANA Plus)


Age group	No. of participants	cVNT₅₀ GMT (95% CI)	Geometric mean ratio (95% CI) vs. 19 to 39 y/o
19-39 y/o	43	127.0 (89.6; 179.80)	
3-18 y/o	131	158.4 (123.0; 204.0)	1.25 (0.77; 2.02)
3-11 y/o	66	181.6 (120.6; 273.3)	1.43 (0.80; 2.54)
12-18 y/o	65	137.9 (101.8; 186.9)	1.08 (0.68; 1.73)

GMT and two-sided 95% confidence intervals were calculated by exponentiating the mean logarithm of the titers and the corresponding confidence intervals (based on the Student's t distribution). The geometric mean ratio and two-sided 95% confidence intervals were calculated by exponentiating the mean difference of the logarithms of the titers (in child/adolescents cohorts minus the 19-39-year-old cohort) and the corresponding confidence intervals (based on the Student's t distribution). The non-inferiority criterion was met, since the lower boundary of the two-sided confidence interval for the geometric mean ratio was greater than 0.67.

315

Based on immunogenicity data of vaccinated children and the immune response to natural infection (children convalescent panel), a prediction of clinical efficacy was estimated through a regression linear model. By using cVNT₅₀ as the predictive variable, the estimated efficacy is 91.3% (Cl 95% 84.6; 95.1) after two doses and 97.4 % (IC 95% 91.5; 99.2) after three doses (Figure 4). This study was conducted in Havana during delta wave; after receiving the first dose 29 children (8.2%) of 350 children became PCR-positive, this value dropped down to 13 (4.0%) out of 321 children after completing the two-dose scheme.





324

Figure 4. Prediction of clinical efficacy in children from correlation between antibody responses and 325 efficacy rate. Panels displays correlation of cVNT₅₀ neutralization and ratios, respectively for seven 326 vaccines in adults; SOBERANA 02 and SOBERANA Plus in children. The y-axis is estimated log risk ratio 327 reported on the vaccine efficacy scale. The x-axis is log ratio of the peak geometric mean neutralization 328 at 7-28 days post-vaccination, relative to human or children convalescent sera. 329

330

331 Discussion.

332 This study describes, for a first time, the safety and immunogenicity in children 3-18 y/o of two doses of SOBERANA 02, followed by a heterologous third doses of SOBERANA Plus. The frequency of local 333 and systemic AE was 49.0% and 2.6% respectively, lower than after mRNA COVID-19 vaccination 334 (Frenck et al., 2021; Ali et al., 2021). After two doses, BNT162b2 reported 86.0% and 66.0 of children 335 12-15 y/o with local and systemic AEs while mRNA-1273 reported 94.2% and 68.3% (aged 12-17 y/o) 336 respectively (Frenck et al., 2021; Ali et al., 2021). In our study, local pain was reported by the 51.4% of 337 children aged 12-18 y/o after first dose, 17% after the second and 17.3% after the third one. BNT162b2 338 and mRNA-1273 vaccine in adolescents reported 86.0% and 94.2% with local pain after first dose; and 339 79.0% and 92.4% after the second, respectively (Frenck et al., 2021; Ali et al., 2021). SOBERANA 02 340 and SOBERANA Plus caused general discomfort (the most frequent systemic AE) only in 1.7% of 341 children 12-18 y/o, while mRNA vaccines provoked fatigue, headache, chills, muscle pain or fever in 10-342 68.5% of adolescents (Frenck et al., 2021; Ali et al., 2021). In children aged 3-11 local pain was the 343 unique EA with frequency >10% during this study; children aged 5-11 vaccinated with BNT162b2 344 reported local pain (74.0%), redness (19.0%), swelling (15.0%), fatigue (39.0%) and headache (28.0%) 345

346 (Walter et al., 2021). Myocarditis and pericarditis have been reported in adolescent after mRNA COVID-

19 vaccination (Oster et al., 2021; Marshall et al., 2021); these AEs were not observed here.

348 The comparison of the humoral immune response elicited by vaccination with the elicited by natural

infection has been a useful tool for the development of several anti-SARS-CoV-2 vaccine (Keech et al.,

2020; Yang et al., 2021). Two shots of SOBERANA 02 every 28 days in children induced a robust

humoral response, with higher levels of antibodies and similar neutralizing capacity of the elicited by

natural infection. The third dose of SOBERANA Plus boosted both the production of antibodies and their

neutralizing capacity, surpassing the immune response in convalescent children, as had been

previously observed in clinical trials in adults (Toledo-Romani et al., 2021a; 2021b).

The induction of specific T-cell response is critical for protection of viral infections. The heterologous

three doses schedule in children developed a balanced activation of IFN- γ and IL-4-secreting cells from

PBMC, indicating a mixed Th1/Th2 response, as reported in adults after the same vaccination scheme

358 (Toledo-Romani et al., 2021a).

359 The SARS-CoV-2 variants of concern alpha, beta, delta, and recently, omicron have modified the

pandemic landscape worldwide (Fontane et al., 2021). Here, we report the capacity of anti-RBD

antibodies for neutralizing alpha, beta and delta variant, with a fold-reduction of 2.2 for delta and 7.0 for

beta compared to D614G, as we found in adults (Toledo-Romani et al., 2021b). In an independent study

from the "Pedro Kourí" Tropical Medicine Institute in Havana, sera from 20 adults vaccinated with

364 SOBERANA 02 + SOBERANA Plus neutralize the omicron variant (Portal-Miranda 2022; Carles JM,

365 2022). Recently, the Pasteur Institute of Iran informed that Pasteurcovac, the Iranian brand of

366 SOBERANA 02, is 100% effective against the omicron variant in adults (Biglari 2022).

367 We conducted this clinical trial during the delta wave, the worst period of Cuban epidemic (Rodriguez;

368 2021); in such a context and due to ethical reasons, a placebo-controlled clinical trial was not ethical.

Lacking a control group (main limitation of the trial), two analytical tools complemented the study:

immunobridging with the immune response in young adults previously vaccinated during clinical trial

with same vaccination schedule (no concurrent reference population) as recommended by FDA, 2021;

and prediction of clinical efficacy based on immunological response (Khoury et al., 20211; Kristen et al.,

2021). Firstly, we found a non-inferior response for the ratio of SARS-CoV-2 cVNT₅₀ after the three-

dose scheme in participants 3-11 and 12-18 y/o relative to a 19-39 y/o reference population (no

concurrent) The comparison met the non-inferiority criterion with ratio 1.43 (CI 95% 0.8-2.54) for 3-11

y/o and 1.08 (CI 95% 0.68-1.73) for 12-18 y/o, satisfying FDA recommendations (FDA, 2021). Similar

analyses have been reported by BNT162b2 and mRNA-1273 vaccines but using 19-25 y/o as reference

population (Walter et al., 2022; Ali et al., 2021). Based on published results, we considered young

adults as immunocompetent up to 39 years (Lopez-Sejas 2016; Ventura et al., 2017; Thapa and Farber 379 2019); this increased the number of $cVNT_{50}$ data for comparison in the reference population. 380 Secondly, a prediction of clinical efficacy based on immunological response has been advanced for 381 other vaccines (Khoury et al., 20211; Kristen et al., 2021). Using this model, for adults aged 19-80 we 382 anticipated a clinical efficacy between 58% and 87% after first two doses and between 81% and 93% 383 after the three-dose scheme (Toledo-Romani et al., 2021b). These results were confirmed during a 384 phase III clinical trial reporting a 71% of efficacy for the two-dose schedule of SOBERANA 02 and 385 92.4% for the heterologous three-dose schedule (Toledo-Romani et al., 2021c). Here, the model 386 predicts 89.3%-91.3% clinical efficacy after two doses of SOBERANA 02 and 95.1%-97.4% after the 387

- third doses of SOBERANA Plus in children versus the D614G strain.
- 389 Starting children vaccination at 2 y/o is key for controlling the pandemic, cutting the transmission and
- reducing the emergence of new VOCs (Petersen and Buchy, 2021). The safety and immunological
- results reported here supported the emergency use authorization of SOBERANA 02 and SOBERANA
- 392 Plus as heterologous scheme for children between 2-18 y/o. A massive immunization campaign started
- on 5th September 2021; fully vaccinating 1.8 millions of Cuban children (96% of 2-18 y/o Cuban
- population (Redd, 2022; Augustin, 2022). These results support public health vaccination strategies,
- providing children as young as two years a safe and effective vaccine scheme to prevent COVID-19.
- 396

397 Funding

This work was supported by the Finlay Vaccine Institute, BioCubaFarma and the National Funds for

- Sciences and Technology from the Ministry of Science, Technology and Environment (FONCI-CITMA-
- 400 Cuba, contract 2020-20).
- 401 Declaration of Interests
- 402 The authors R.P.G, Y.R.D, C.R.I, L.C.H. M.P.B, D.V.M, N.P.P, C.V.S, A.P.D, E.G.O, Y.C.E, J.C.F.P,
- M.S.M, M.D.E, J.M.E.P, Y.I.H, M.E.T.R declare that they have no known competing financial interestsor personal relationships that could have appeared to influence the work reported in this paper.
- 405 The authors B.P.M, M.R.G, B.S.R, L.M.R.N, R.P.N, R.G.M, T.H.G, T.F.B, I.C.Q, S.F.C, Y.C.R, D.S.M,
- 406 Y.G.V, Y.V.B, D.G.R, V.V.B work at Finlay Vaccine Institute or the Centre of Molecular Immunology,
- 407 institutions that develop and manufacture the vaccine candidates but they haven't received an
- 408 honorarium for this paper.
- B.S.R., S.F.C., Y.C.R, L.R.N., D.S.M., Y.V.B., D.G.R. and V.V.B., have filed patent applications related
- 410 to the vaccine SOBERANA 02.
- 411 D.D and A.B work at Pasteur Institute of Iran and are co-developer of the vaccines
- 412 Acknowledgments

413 We especially thanks all the parents and children for participated in the clinical trial. We recognize the

contribution of all the medical and nurse staff at clinical site. We thank Dr. Lila Castellanos for scientific

415 advice.

- 416 References
- Ali K, Berman G, Zhou H, Deng W, Faughnan V, Coronado-Voges M, et al. Evaluation of mRNA-1273
- 418 SARS-CoV-2 Vaccine in Adolescents. N Engl J Med 2021; 385: 2241-51. doi: www.www
- Augustin Ed . Cuba leads the world in vaccinating children as young as two against Covid. The
- Guardian. February 1st, 2022. <u>https://www.theguardian.com/world/2022/feb/01/cuba-leads-world-</u>
 <u>vaccinating-children</u> (Accessed February 17th, 2022)
- Avci FY, Li X, Moriya T, Kasper D. A mechanism for glycoconjugate vaccine activation of the adaptive
 immune system and its implications for vaccine design. Nature Medicine 2011;17:1602-10. doi:

424 https://doi.org/10.1038/nm.2535

Biglari A. Official says Pasteurcovac 100% effective against Omicrom variant. Islamic Republic News

426 Agency. <u>https://en.irna.ir/news/84638920/Official-says-Pasteurcovac-100-effective-against-</u>

427 <u>Omicrom-variant</u> 2022. (Accessed February 11th 2022)

- 428 Carles Zerquera JM. Cuban's vaccines against Omicron. Rapid response to
- 429 BMJ 2022; 376 doi: https://doi.org/10.1136/bmj.o66; January 29th, 2022 Available in:
- 430 <u>https://www.bmj.com/content/376/bmj.o66/rapid-responses (Accessed February 17th, 2022)</u>
- 431 CECMED Cuban National Regulatory Agency. Resolution 144/2021. Authorization for emergency use of
 432 SOBERANA02 in adults. <u>https://www.cecmed.cu</u> 2021 (Accessed November 17th; 2021)
- 433 Dal-Ré R, Caplan A. Current COVID-19 vaccine trials in high-income countries: are placebo-controlled
 434 trials ethical? Clin Microbiol Infect 2021;27:1565-67. doi: 10.1016/j.cmi.2021.08.005
- 435 Delahoy M, Ujamaa D, Whitaker M, O'Halloran A, Anglin O, Burns E, et al. Hospitalizations Associated
- with COVID-19 Among Children and Adolescents COVID-NET, 14 States, March 1, 2020–

437 August 14, 2021. MMWR Morb Mortal Wkly Rep 2021;70:1255–60. doi:

438 10.15585/mmwr.mm7036e2

Earle K, Ambrosino D, Andrew Fiore-Gartland; Golblatt D, Gilbert PB, et. al. Evidence for antibody as a
protective correlate for COVID-19 vaccines. Vaccine 2021;39:4423–28. doi:
https://doi.org/10.1016/j.vaccine.2021.05.063

Elliott P, Bodinier B, Eales O, Wang H, Haw D, Elliott J, et al. Rapid increase in Omicron infections in

England during December 2021: REACT-1 study. Science 2022; doi: 10.1126/science.abn8347

- 444 FDA. Vaccines and Related Biological Products Advisory Committee Meeting. June 10, 2021.
- Licensure and Emergency Use Authorization of Vaccines to Prevent COVID-19 for Use in Pediatric
- 446 Populations. <u>https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-</u>

447	related-biological-products-advisory-committee-june-10-2021-meeting-announcement. 2021
448	(Accessed September 14th, 2021)
449	Fontanet A, Autran B, Lina B, Kieny MP, Abdool Karim SS, Sridhar D. SARS-CoV-2 variants and ending
450	the COVID-19 pandemic. Lancet 2021; 397: 952–54. doi: https://doi.org/10.1016/S0140-
451	6736(21)00370-6
452	Frenck R, Klein N, Kitchin N, Gurtman A, Absalon J, Lockhart S et al. Safety, Immunogenicity, and
453	Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. N Engl J Med 2021;385: 239–50. doi:
454	10.1056/NEJMoa2107456
455	Han B, Song Y, Li C, Yang W, Ma Q, Jiang Z et al. Safety, tolerability, and immunogenicity of an
456	inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: A double-blind,
457	randomised, controlled, phase 1/2 clinical trial. Lancet Infect. Dis 2021;21:1645-53. doi:
458	https://doi.org/10.1016/S1473-3099(21)00319-4
459	Huang YL, Wu CY. Carbohydrate-based vaccines: challenges and opportunities. Expert Rev Vaccines
460	2010;9:1257–74 doi: 10.1586/erv.10.120
461	IRCT International Register Clinical Trials. Identifier RPCEC00000374. Phase I-II study, sequential
462	during phase I, open-label, adaptive and multicenter to evaluate the safety, reactogenicity and
463	immunogenicity of a heterologous two-dose schedule of the prophylactic anti-SARS- CoV-2
464	vaccine candidate, FINLAY-FR- 2 and a dose of FINLAY-FR-1A, in Cuban children and
465	adolescents. (COVID-19). https://rpcec.sld.cu/en/trials/RPCEC00000374-En (Accessed December
466	1 st , 2021)
467	Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, et al. Phase 1-2 Trial of a SARS-CoV-2
468	Recombinant Spike Protein Nanoparticle. N Engl J Med 2020;383: 2320-32. doi:
469	https://doi.org/10.1056/NEJMoa2026920
470	Khoury DS, Cromer D, Reynaldi A, Schlub T, Wheatley A, Juno J, et. al. Neutralizing antibody levels are
471	highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nature Medicine
472	2021; 27:1205–11. doi: https://doi.org/10.1038/s41591-021-01377-8
473	Lopez-Sejas N, Campos C, Hassouneh F, Sanchez-Correa B, Tarazona R, Pera A, Solana R. Effect of
474	CMV and Aging on the Differential Expression of CD300a, CD161, T-bet, and Eomes on NK Cell
475	Subsets. Front Immunol 2016;7:1-13. doi: 10.3389/fimmu.2016.00476
476	Marshall M, Ferguson ID, Lewis P, Jaggi P, Gagliardo C, Stewart JC. Symptomatic acute myocarditis in
477	7 adolescents after Pfizer-BioNTech COVID-19 vaccination. Pediatrics 2021;148:2-11. doi
478	e2021052478

- 479 Oster ME, Shay DK, Su JR, Gee J, Creech B, Broder KR et al. Myocarditis cases reported after mRNA-
- Based COVID-19 vaccination in the US from December 2020 to August 2021. JAMA
- 481 2022;327:331-340. doi:10.1001/jama.2021.24110
- 482 Petersen E, Buchy P. Vaccination against SARS-CoV-2 should be included in childhood vaccination
- 483 programs. Int. J Infectious Diseases 2021;106:429–430 doi:
- 484 https://doi.org/10.1016/j.ijid.2021.04.082
- 485 Portal-Miranda JA. Las vacunas cubanas generan anticuerpos ante ómicron: Ese éxito no puede
- 486 Ilevarnos a la confianza. <u>http://www.cubadebate.cu/opinion/2022/01/26/</u> 2022 (Accessed January
 487 26th, 2022)
- Reed G. Cuban COVID-19 Vaccines for Children: Rinaldo Puga MD MS Interview. MEDICC Review 2022;
- 489 24:14-8 doi: https://doi.org/10.37757/MR2022.V24.N1.12
- 490 Rodriguez A. Virus slams Cuba as it races to roll out its new vaccines. ABC News, July 21th, 2021.

491 https://abcnews.go.com/Health/wireStory/virus-slams-cuba-races-roll-vaccines-78953663

- 492 (Accessed February 17th, 2022)
- Thapa P, Farber D. The Role of the Thymus in the Immune Response. Thorac Surg Clin, 2019; 29:123131 doi: 10.1016/j.thorsurg.2018.12.001
- 495 Toledo-Romani ME, Garcia-Carmenate M, Valenzuela-Silva C, Baldoguin-Rodriguez W, Martínez-Pérez M, Rodríguez-Gonzalez MC, et al. Efficacy and Safety of SOBERANA 02, a COVID-19 conjugate 496 497 vaccine in heterologous three doses combination. MedRxiv 2021c doi: https://doi.org/10.1101/2021.10.31.21265703 498
- Toledo-Romani ME, García-Carmenate M, Verdecia-Sánchez L, Pérez-Rodríguez S, Rodriguez-
- 500 González M, Valenzuela-Silva C. et al. Safety and immunogenicity of anti-SARS CoV-2 conjugate 501 vaccine SOBERANA 02 in a two-dose or three-dose heterologous scheme in adults: Phase IIb 502 Clinical Trial MadDvik 2021b dai: https://doi.org/10.1101/2022.01.01.212(.0271
- 502 Clinical Trial. MedRxiv 2021b doi: <u>https://doi.org/10.1101/2022.01.01.21268271</u>
- Toledo-Romani ME, Verdecia-Sánchez L, Rodriguez-González M, Rodríguez-Noda L, Valenzuela-Silva
 C, Paredes-Moreno et al. Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02
 in homologous or heterologous scheme. MedRxiv 2021a doi:
- 506 https://doi.org/10.1101/2021.11.14.21266309
- Valdes-Balbin Y, Santana-Mederos D, Paquet F, Fernandez S, Climent Y, Chiodo F et al. Molecular
 Aspects Concerning the Use of the SARS-CoV-2 Receptor Binding Domain as a Target for
- 509Preventive Vaccines. ACS Cent Sci 2021;7:757-67. doi:
- 510 https://doi.org/10.1021/acscentsci.1c00216

- 511 Valdes-Balbin Y, Santana-Mederos D, Quintero L, Fernandez S, Rodriguez L, Sanchez-Ramírez B et al.
- 512 SARS-CoV-2 RBD-Tetanus toxoid conjugate vaccine induces a strong neutralizing immunity. ACS
- 513 Chem Biol 2021;16:1223–33. doi: <u>https://doi.org/10.1021/acschembio.1c00272</u>
- 514 Ventura MT, Casciaro M, Gangemi S, Buquicchio R. Immunosenescence in aging: between immune
- cells depletion and cytokines up-regulation. Clin Mol Allergy 2017; 15:21 doi:
- 516 <u>https://doi.org/10.1186/s12948-017-0077-0</u>
- 517 Verez-Bencomo V, Fernandez-Santana V, Hardy E, Toledo ME, Rodriguez MC, Heynngnezz L et. al. A
 518 synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type b. Science
- **519** 2004;305: 522-525 doi: 10.1126/science.1095209
- 520 Wallace M, Woodworth KR, Gargano JW, Scobie HM, Blain M, Moulia D et al. The Advisory Committee
- on Immunization Practices' interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine
- in adolescents aged 12–15 years—United States, May 2021. MMWR Morb Mortal Wkly Rep
- 523 2021;70:749–52. doi: <u>https://doi.org/10.15585/mmwr.mm7020e1</u>
- Walter EB, Talaat KR, Sabharwal C, Gurtman A, Lockhart S, Paulsen GC et al. Evaluation of the
 BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. N Engl J Med 2022;386:35-46 doi:
- **526** 10.1056/NEJMoa2116298
- WHO COVID-19 Landscape of novel coronavirus candidate vaccine development worldwide.
 <u>https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines</u>, 2021
- 529 (accessed December 29th, 2021)
- World Health Organization. Causality Assessment of an Adverse Event Following Immunization (AEFI).
 2nd Edition. Geneva: WHO; 2019. ISBN: 9789241516990
- 532 <u>https://www.who.int/publications/i/item/causality-assessment-aefi-user-manual-2019</u> 2019
- **533** (Accessed June 17th, 2021)
- Xia S, Zhang YT, Wang Y, Wang H, Yang Y, Fu-Gao G et al. Safety and immunogenicity of an
 inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised,
- double-blind, controlled, phase 1/2 trial. Lancet Infect Dis 2022;22:196-208. doi: 10.1016/S14733099(21)00462-X
- Yang S, Li Y, Dai L, Wang J, He P, Li C, et al. Safety and immunogenicity of a recombinant tandemrepeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two
- randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect Dis. 2021; 21:1107-
- 541 11. doi: <u>https://doi.org/10.1016/S1473-3099(21)00127-4</u>